tiprankstipranks
Is TAK a Buy, Before Earnings?
PremiumPre-EarningsIs TAK a Buy, Before Earnings?
25d ago
Spyre Therapeutics price target raised to $65 from $50 at Guggenheim
Premium
The Fly
Spyre Therapeutics price target raised to $65 from $50 at Guggenheim
28d ago
Takeda and BMC team on decarbonization across health care ecosystem
Premium
The Fly
Takeda and BMC team on decarbonization across health care ecosystem
29d ago
Firefly Neuroscience collaborates with Takeda, Novartis
PremiumThe FlyFirefly Neuroscience collaborates with Takeda, Novartis
2M ago
Takeda receives European Commission approval for ADZYNMA
Premium
The Fly
Takeda receives European Commission approval for ADZYNMA
4M ago
Protagonist Therapeutics price target lowered to $43 from $45 at JMP Securities
Premium
The Fly
Protagonist Therapeutics price target lowered to $43 from $45 at JMP Securities
4M ago
Takeda Advances Sustainable Pharma Innovation
PremiumCompany AnnouncementsTakeda Advances Sustainable Pharma Innovation
5M ago
Takeda: Japanese MHLW approves LIVTENCITY
Premium
The Fly
Takeda: Japanese MHLW approves LIVTENCITY
5M ago
Takeda receives approval from European Commission for FRUZAQLA
Premium
The Fly
Takeda receives approval from European Commission for FRUZAQLA
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100